Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 +0.48%74 PE Ratio without NRI is 21.07 as of Jul. 15, 2026, which is 41% below its 10-year median of 35.72. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 96 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 68.75% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-15), Diva Laboratories's share price is NT$31.40.
Diva Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.49. Therefore, Diva Laboratories's PE Ratio without NRI for today is 21.07.
During the past 13 years, Diva Laboratories's highest PE Ratio without NRI was 116.61. The lowest was 15.82. And the median was 35.72.
Diva Laboratories Ltd stock PE Ratio (=20.29) is close to 10-year low of 19.51.
During the past years, Diva Laboratories's highestPE Ratio (TTM) was 408.87. The lowest was 19.51. And the median was 41.16.
Diva Laboratories's
EPS (Diluted) for the
three
months ended in Dec. 2025 was NT$0.50.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.53.
Diva Laboratories's EPS (Basic) for the
three
months ended in Dec. 2025 was NT$0.50.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.53.
Diva Laboratories (ROCO:4153) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Diva Laboratories PE Ratio without NRI Related Terms
Diva Laboratories PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, IDXX: PE Ratio without NRI Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's PE Ratio without NRI falls into.
Diva Laboratories PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Diva Laboratories's Share Price of today is NT$31.40.
Diva Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.49.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Diva Laboratories (ROCO:4153) has a PE Ratio without NRI of 21.07 as of Jul. 15, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Diva Laboratories and its competitors. This is 41% below median its historical median of 35.72. Over the past decade, Diva Laboratories' PE Ratio without NRI has ranged from 15.82 to 116.61. According to the industry distribution chart, Diva Laboratories ranks #30 out of 96 companies in the Medical Diagnostics & Research industry, placing it in the top 31.2%.
Is Diva Laboratories' PE Ratio without NRI too high?
Diva Laboratories' current PE Ratio without NRI of 21.07 is 41% below median its 10-year median of 35.72. Over the past 10 years, this metric has ranged from a low of 15.82 to a high of 116.61. The Medical Diagnostics & Research industry median PE Ratio without NRI is 30.57. Diva Laboratories' value of 21.07 is 31.1% below this industry median. Based on the distribution chart, Diva Laboratories ranks #30 out of 96 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' PE Ratio without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #30 out of 96 companies for PE Ratio without NRI. This puts Diva Laboratories in the upper half of its industry. The industry median PE Ratio without NRI is 30.57. Diva Laboratories' value of 21.07 is 31.1% below this benchmark. Historically, Diva Laboratories' own PE Ratio without NRI has ranged from 15.82 to 116.61 over the past decade. While the company's 10-year median is 35.72 vs. the industry median of 30.57, Diva Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 30.57, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current PE Ratio without NRI of 21.07 is 31.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 30.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current PE Ratio without NRI is 21.07, which is 41% below median its own 10-year median of 35.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current PE Ratio without NRI is 21.07, which is 41% below median its 10-year median of 35.72 and 31.1% below the Medical Diagnostics & Research industry median of 30.57. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current PE Ratio without NRI is 21.07 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
PE Ratio without NRI: 21.07 (41% below median its 10-year median of 35.72)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
Industry Position: 31.1% below the Medical Diagnostics & Research median (#30 of 96)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
